Article

Molecularly Adapted Antitumor Therapy for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Two-Year Follow-Up Results

2026-02-20

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) is molecularly heterogeneous; genotype-directed first-line therapy may improve outcomes. We conducted a single-center, prospective, non-randomized interventional study evaluating a molecularly adapted R-CHOP-X strategy with two-year follow-up. Between February 2023 and the data cut-off (September 16, 2025), 43 adults with newly diagnosed DLBCL (excluding high-grade B-cell lymp...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8fc64f07-0506-54a8-b3a5-c9d9116205f2
DOI: 10.20944/preprints202602.1345.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Molecularly Adapted Antitumor Therapy for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Two-Year Follow-Up ResultsDOI 10.20944/preprints202602.1345.v1Read

A53-Adapted Decitabine-Containing R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma Defined by LymphGen: Preliminary Results of a Prospective Proof-of-Concept StudySemantic proximity Read

TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era.Semantic proximity Read

Next-generation prognostic assessment for diffuse large B-cell lymphoma.Semantic proximity Read

Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.Semantic proximity Read

Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study.Semantic proximity Read

[Mutational Spectrum and Prognosis Analysis of Young Patients with Diffuse Large B-Cell Lymphoma Based on Next-Generation Sequencing].Semantic proximity Read

Real-world Outcomes of Diffuse Large B-cell Lymphoma Treated with frontline R-CHOP(-like) regimens in an Asian Multi-ethnic PopulationSemantic proximity Read

The Impact of Genetic Subtypes of Diffuse Large B-Cell Lymphoma for Outcome Prediction and Interpretation of FDG-PET treatment Response MonitoringSemantic proximity Read

Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.Semantic proximity Read

A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCLSemantic proximity Read

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.Semantic proximity Read

The treatment of Burkitt lymphoma in adults.Semantic proximity Read